You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
WALTHAM, Mass. , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO and Charles Morris , Chief Medical Officer of the Company will present a corporate update at the Leerink Partners Oncology Roundtable Series on Wednesday,
WALTHAM, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will
WALTHAM, Mass. , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO, and Pepe Carmona , Chief Financial Officer of the Company, will present a corporate update at the Morgan Stanley 16th Annual Global Health Care Conference
WALTHAM, Mass. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors granted Dr. Charles Morris , in connection with his appointment as the Company’s Chief Medical Officer, an option to purchase
WALTHAM, Mass. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the appointment of Dr. Charles Morris as Chief Medical Officer. Dr. Morris will oversee and lead all clinical development, regulatory and medical affairs strategies and
Second quarter 2018 TYMLOS sales increase to $22.6 million, a 56% increase over the first quarter of 2018 TYMLOS' share in the U.S. anabolic osteoporosis market increased to an average of 19% in the second quarter from 13% in the prior quarter Radius maintains its 19-21% average 2018 U.S.
WALTHAM, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced that
WALTHAM, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter financial results on Tuesday, August 7, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m.
WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced that the Compensation Committee of the Company's Board of Directors granted Chhaya Shah, in connection with her appointment as the Company's Senior Vice President,
WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations. "Ms. Shah will help strengthen and expand our technical operations infrastructure,
